Today, Biogen completed the acquisition of immune-mediated disease company HI-Bio. Learn more about the acquisition: https://ow.ly/uVKJ50StGbo
Congrats on this achievement.
Congratulations to both teams!
Fantastic update!
Congrats Houston!
Skip to main content
Today, Biogen completed the acquisition of immune-mediated disease company HI-Bio. Learn more about the acquisition: https://ow.ly/uVKJ50StGbo
Congrats on this achievement.
Congratulations to both teams!
Fantastic update!
Biomarker/Biospecimen Operations/Translational Medicine/Precision Medicine Professional
3moCongrats Houston!
To view or add a comment, sign in
Increasing numbers of IPF studies and a limited pipeline of participants mean researchers need novel strategies for drug development. Learn how to navigate the changing landscape of research on this rare disease in this blog from our experts. https://ow.ly/VVtR50SwIri
To view or add a comment, sign in
ICT Spring 2024 is now live! ☀️ Featuring insights in Decentralised Clinical Trials, Orphan Drug and Rare Disease Trials, and much more! Read here: https://bit.ly/3URlpxX #ClinicalTrials #decentralisedclinicaltrials #rarediseases #orphandrugs #pharmaceuticalindustry
To view or add a comment, sign in
Diagnostic sales specialist - Helping you accelerate the development and commercialization of diagnostic assays and kits
Article | What’s hot in molecular diagnostics and where it’s going Staying informed on the latest trends in molecular-diagnostics is key to staying ahead in the fight against disease. Read our blog to find out what’s hot in molecular-diagnostics, and where we are taking it. https://lnkd.in/dUHXesMb #diagnostics #immunodiagnostics #lifesciences #biopharma
To view or add a comment, sign in
If you are planning rare disease research, this webinar recording is a must see. Learn how early market-access evidence planning for your orphan drug can help gather the right evidence for reimbursement and access - the first time. View now. http://ow.ly/twtw50J9VHv #marketaccess #drugdevelopment
To view or add a comment, sign in
ICT Spring 2024 is now live! ☀️ Featuring insights in Decentralised Clinical Trials, Orphan Drug and Rare Disease Trials, and much more! Read here: https://bit.ly/3URlpxX #ClinicalTrials #decentralisedclinicaltrials #rarediseases #orphandrugs #pharmaceuticalindustry
ICT Spring 2024 is now live! ☀️ Featuring insights in Decentralised Clinical Trials, Orphan Drug and Rare Disease Trials, and much more! Read here: https://bit.ly/3URlpxX #ClinicalTrials #decentralisedclinicaltrials #rarediseases #orphandrugs #pharmaceuticalindustry
To view or add a comment, sign in
US & #APAC Rare Disease Pharma & #Biotech Leaders: Did an #FDA setback derail your #raredisease therapy development? The European pathway could be your strategic advantage. The #EMA offers: 💚 Alternative pathways: Flexibility in trial design & accelerated assessment for unmet needs. 💚 Valuable insights: Address FDA concerns using EMA feedback. 💚 Early market access: Potentially secure approval & generate data for US payers. Dive into part 2 of our "Don't Sleep on the EU" series: The Global Ambition: Mastering Dual Submission for Rare Disease Therapies. https://lnkd.in/dGSGHCuR 💛 Next week's final article, "Hurdles to Harmonization," explores how to leverage EU success for a triumphant return to the #FDA after experiencing a setback. Stay tuned! #biotech #pharma #globalstrategy #drugdevelopment #clinicaltrials #marketaccess
To view or add a comment, sign in
We are excited to announce our latest partnership with n-Lorem Foundation to develop personalized antisense oligonucleotide (ASO) treatments for patients with ultra-rare and nano-rare diseases. In many cases, nano-rare patients will succumb to their disease without ever having hope of a treatment that will halt their progressive diseases. But working with n-Lorem, we hope to change this. We will provide amidites, compounds essential to developing ASO medicines, to n-Lorem to help offset the costs of developing ASO medicines for up to 20 nano-rare patients. Learn more from Wei Jiang and Stanley Crooke about this exciting partnership below. 👇 https://loom.ly/zDaQhRk #RareDiseases #DrugDevelopment #Oligonucleotides
To view or add a comment, sign in
The results from Arrowhead Pharmaceuticals' Phase 3 PALISADE study on plozasiran are truly impressive and could be a game-changer for patients with familial chylomicronemia syndrome (FCS). I'm excited by the potential impact this could have on a condition that currently has no approved treatments in the U.S. The involvement of experts like Gerald F. Watts and Bruce Given, M.D. adds significant weight to these findings. Their work not only showcases the power of RNAi therapeutics but also highlights how targeted innovation can meet critical, unmet medical needs. If plozasiran is approved, it could dramatically improve the quality of life for FCS patients, and it’s exciting to see this kind of progress in the field. #RNAi #FCS #research #Biotechnology
To view or add a comment, sign in
Unlocking Access to Life-Changing Therapies: Discover how orphan drugs are transforming the lives of those affected by rare diseases. Swipe through to learn about the challenges, strategies, and our commitment at BioXplore to making these vital treatments accessible to all. 💊✨ #RareDiseaseAwareness #OrphanDrugs #HealthTechnology #PatientAccess #PharmaInnovation #HealthcareStrategy #BioXplore #ValueAssessment #PatientAdvocacy #LifeChangingTherapies #MedicalBreakthroughs #DrugDevelopment #HealthcareSolutions #MarketAccess #PharmaceuticalIndustry
To view or add a comment, sign in
1,031,435 followers
Great news! felzartamab looks to be very promising across a number of indications.